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Abstract
Introduction: no previous studies had reported the prevalence of cardiometabolic diseases various regions of Venezuela. Objective: to 
determine the prevalence of cardiometabolic risk factors in 3 populations of Venezuela. Methods: the VEMSOLS study is a sub-national, 
cross-sectional, population based, with bi-stage random sampling study, evaluating 751 subjects aged 20 or older from 3 selected 
municipalities of Venezuela. Anthropometric and biochemical measurements were obtained. ANOVA was used to continous variables 
and Chi-square to proportions, a p<0.05 was significant. Results: 69% were females and 81.4% from urban areas. Low HDL-c was the most 
prevalent disorder (63.8% [–CI- 95% 60.1-67.4]), being more common in women than in men (74.1% [69.9 -77.9] and 40.4% [33.7-43.4], 
respectively, p < 0.05); followed by abdominal obesity (47.4% [43.8 -51.1]) and hypertriglyceridemia (45.2% [41.5 - 49.0]). One third (30.0% 
[26.7-33.4]) had hypertension, 11.8% (9.5 -14.5) diabetes, 23.1%  (20.2-26.3) obesity, and 20.1% (17.2-23.4) elevated LDL-cholesterol. Metabolic 
syndrome was present in 29.9% (26.5-33.5) of the sample. Rural population from the Andeans mountains (Páramo) presented a lower 
prevalence of obesity and low HDL-c (p < 0.05) comparing with urban samples. Lara’s population, which had the highest Body Mass Index 
of the 3 municipalities, had a higher prevalence of abdominal obesity, atherogenic dyslipidemia and elevated LDL-c than the other two 
populations (p < 0.05). Conclusion: A high prevalence of cardiometabolic abnormalities in 3 populations of Venezuela was observed with 
a lower prevalence of alterations in the rural area. MÉD.UIS. 2018;31(1):15-22.
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Prevalencia de factores de riesgo cardiometabólico en 3 poblaciones de 
Venezuela: estudio VEMSOLS 2006-2010
Resumen
Introducción: ningún estudio ha reportado la prevalencia de factores de riesgo cardiometabólico en varias regiones de Venezuela. 
Objetivo: determinar la prevalencia de factores de riesgo cardiometabólico en 3 poblaciones de Venezuela. Materiales y Métodos: el 
estudio VEMSOLS es un estudio sub-nacional, transversal, poblacional, de muestreo aleatorio bi-etápico, evaluando 751 sujetos de 20 o 
más años de edad de 3 municipios de Venezuela. Mediciones antropométricas y bioquímicas  fueron obtenidas. Analysis of Variance se 
utilizó para variables continuas y Chi-cuadrado para proporciones, significancia fue p<0,05. Resultados: 69% fueron mujeres y 81,4% del 
área urbana. Colesterol HDL bajo fue la alteración más prevalente (63,8% [Intervalo de Confianza –IC- 95%: 60,1-67,4]), siendo más común 
en mujeres que en hombres (74,1% [69,9 -77,9] y 40,4% [33,7-43,4], respectivamente, p< 0,05); seguidos por obesidad abdominal (47,4% 
[43,8 -51,1]) e hipertrigliceridemia (45,2% [41,5 – 49,0]). Un tercio (30,0% [26,7-33,4]) tenía hipertensión, 11,8% (9,5 -14,5) diabetes, 23,1%  (20,2 
– 26,3) obesidad y 20,1% (17,2-23,4) colesterol LDL elevado. El síndrome metabólico estuvo presente en 29,9% (26,5-33,5) de la muestra. 
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La población rural de los Andes (Páramo) presentó una baja prevalencia de obesidad y colesterol HDL bajo comparado con las muestras 
urbanas (p < 0,05). La población de Lara, quien tenía el índice de masa corporal más elevado de las 3 municipalidades, mostró una alta 
prevalencia de obesidad abdominal, dislipidemia aterogénica y colesterol LDL elevado en comparación con las otras dos poblaciones 
(p< 0.05). Conclusión: se observó una elevada prevalencia de anormalidades cardiometabólicas en 3 poblaciones de Venezuela con una 
menor prevalencia de alteraciones en el área rural. MÉD.UIS. 2018;31(1):15-22.
Palabras clave:  Obesidad. Hipertensión. Diabetes Mellitus.
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Introduction
Non-communicable diseases (NCDs) are the 
leading cause of global death, representing 68% (38 
million) of the world’s 56 million deaths in 20121. 
Cardiovascular disease comprised the major cause of 
NCD deaths responsible for 17.5 million deaths (46% 
of NCD deaths)1. In Venezuela, the crude mortality 
rate of diabetes, coronary and cerebrovascular 
disease, increased from 33 255 deaths (33.7%) in 1995 to 
55 454 deaths (35.9%) in 20112. Classic factors as high 
cholesterol, smoking, hypertension, high body mass 
index (BMI), and family history of coronary heart 
disease, accounted for 76% of cases of myocardial 
infarction in this country3.
Only two mayor well designed studies had previously 
reported the prevalence of cardiometabolic risk 
factors in Venezuela. The Cardiovascular Risk Factor 
Multiple Evaluation in Latin America (CARMELA) 
study that included 11 550 subjects from seven 
Latin American cities, reported that Barquisimeto 
city (Venezuela) occupied the second place of 
prevalence of metabolic syndrome (25.8%), 3rd 
place in hypertension (24.7%), 3rd place in obesity 
(25.1%); with a lower prevalence of diabetes (6.0%, 
5th place), hypercholesterolemia (5.7% 7th place), 
and cigarette smoke (21.8%, 7th place)4. The study 
of Cardiac Coronary Disease Risk Factors from 
Zulia state evaluated 3 108 subjects reporting a 
high prevalence of metabolic syndrome (32.2%), 
atherogenic dyslipidemia (24.1%), low concentration 
of high density lipoproteins cholesterol (HDL-c) 
(65%), abdominal obesity (43%), and elevated blood 
pressure (38%)5. 
Despite this reports, no previous studies had reported 
the prevalence in more than one region of Venezuela, 
this creates a knowledge  gap necessary to stablish 
proper public politicies in Venezuela, prompting 
the design of the Venezuelan Metabolic Syndrome, 
Obesity and Lifestyle Study (VEMSOLS). This paper 
presents the results of VEMSOLS, specifically, the 
prevalence of cardiometabolic risk factors composed 
by increased weight, higher blood pressure, 
dysglycemia, and metabolic syndrome,  of three 
populations, including two urban and one rural area 
from two regions of Venezuela.
Methods
1. Design and Subjects
An observational, cross-sectional study was designed 
to determine the prevalence of cardiometabolic 
risk factors in a sub-national sample of Venezuela. 
The sample size was calculated to detect a 
hypercholesterolemia prevalence (the lowest 
prevalent condition reported in Venezuela) of 5.7%4 
with a standard deviation of 1,55%, which allows to 
calculate a 95% confidence interval (95% CI). The 
minimal estimated number of subjects to be evaluated 
was 830. Overall, 1320 subjects were evaluated in five 
cities from three regions in Venezuela.  In this paper, 
we analyzed and compared in detail three populations 
from two regions: Palavecino Municipality in Lara 
State (urban n=339) from the Western region which 
is an important urban, industrial, commercial and 
transportation center of the country located at 622 
metres above sea level; Ejido Municipality (Mérida 
city) in Merida State (urban n= 272) located at 1600 
metres above sea level; and Rangel Municipality 
(Páramo area) in Merida State (rural n= 140), these 
last two from Andeans region. The rural population, 
defined as those with territory not included within an 
urban area with less than 50 000 habitants, is located 
in the Páramo Mountains at 3000 meter over the sea 
level, predominantly dedicated to agriculture. During 
the years 2006 to 2010, a total of 750 subjects aged 
20 or older that had lived in their houses at least six 
months were selected by bi-stage random sampling 
multistage stratified random sampling. Each 
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region was stratified by municipalities and one was 
randomly selected. Map and census of each location 
were required to delimit the streets or blocks, and 
to select the households to visit in each municipality. 
After selecting the sector to be surveyed at each 
location, the visits to households started from 
number one onwards skipping every two houses. 
Pregnant women and participants with inability to 
stand up and/or have verbal communication were 
excluded.
2. Clinical and biochemical data
All subjects were evaluated in their home or in a nearby 
health center by a trained health team according to a 
standard protocol. This health team was composed 
of volunteer’s medical students from basic and 
postgraduate6, and the principal investigators of 
the study, who provided a two-days training to the 
collaborators. Each home was visited twice. In the first 
visit, the participants received information about the 
study and the written informed consent was obtained. 
Demographic and clinical information was obtained 
using a standardized questionnaire. Blood pressure 
was measured twice in the right arm supported to 
the heart level, in sitting position, after five minutes 
of rest, with a calibrated aneroid sphygmomanometer 
or mercury sphygmomanometer in the rural sample. 
Weight was measured with the fewest clothes 
possible, without shoes, using a calibrated scale. 
Height was measured using a metric tape on the wall. 
Body mass index (BMI; weight [kg]/height[m]2) was 
calculated. Waist circumference was measured at the 
iliac crest, in a horizontal plane with the floor at the 
end of expiration.
In the second visit, blood samples were drawn 
after 12 hours of overnight fasting. Samples were 
centrifuged during 15 minutes at 3000 rpm within 
30-40 minutes after collection, and transported 
with dry ice to the central laboratory where were 
properly stored at -40°C until analysis. Questionnaire 
information from absents participants in the first visit 
was collected. Glucose plasma concentration7, total 
cholesterol8, triglycerides9, lipoprotein of low density 
of cholesterol (LDL-c), and HDL-c10, were determinate 
by standard enzymatic colorimetric methods.     
            
3. Categorization of variables
Individuals were classified according to the BMI as 
normal weight (BMI < 25 kg/m2), overweight (BMI ≥ 
25 kg/m2 and < 30 kg/m2), or obese (IMC ≥ 30 kg/m2)11. 
Abdominal obesity was defined according to the cut-
off proposed to Latin-America (waist circumference 
≥ 94 cm in men or ≥ 90 cm in women)12. Hypertension 
was defined as systolic blood pressure ≥ 140 
mmHg or diastolic blood pressure ≥ 90 mmHg, or 
antihypertensive medications use13. Dyslipidemia was 
defined according to the NCEP/ATPIII14 definition, and 
was categorized in 6 types: Hypercholesterolemia (≥ 
240 mg/dL of total cholesterol); low HDL-c (< 40 
mg/dL HDL-c in men and < 50 mg/dL HDL-c in women); 
hypertriglyceridemia (≥ 150 mg/dL of triglycerides); 
mixed dyslipidemia (≥ 150 mg/dL of triglycerides plus 
≥ 240 mg/dL of total cholesterol); high LDL-c (≥ 160 
mg/dL of LDL-c), and atherogenic dyslipidemia (≥ 
150 mg/dL triglycerides plus low HDL-c). Glucose 
alterations where classified as prediabetes if 
fasting glucose was between 100 mg/dL and 125 
mg/dL (impaired fasting glucose), and diabetes 
if fasting plasma glucose was ≥ 126 mg/dL.15 
Participants receiving anti-diabetic medications also 
were considered as diabetic. Metabolic syndrome 
was defined as in the NCEP/ATPIII14 to compare the 
results with studies previously published. These 
criteria include the presence of 3 or more of the 
following abnormalities: waist circumference > 102 
cm in men or > 88 cm in women; triglycerides ≥ 150 
mg/dL; HDL-c level < 40 mg/dL in men or < 50 mg/
dL in women; blood pressure ≥ 130/85 mmHg; and 
fasting blood glucose ≥ 110 mg/dL. 
4. Statistical Analysis
All calculations were performed using the SPSS 20 
software (IBM corp. Released 2011. Armonk, NY: 
USA). Data for continuous variables are presented 
as mean ± standard error of the mean. Differences 
between mean values were assessed by analysis of 
variance (ANOVA), with Bonferroni adjustment for 
multiple comparisons. Proportion of subjects with 
obesity, hypertension, dyslipidemia, prediabetes, 
diabetes, and metabolic syndrome, were presented 
as prevalence rates and 95% confidence intervals 
(95% CI). Chi square test was applied to compare 
different frequencies by gender and between the 
three regions. A p-value of < 0.05 was considered to 
be statistically significant.
Results
Subjects Characteristics
Overall, 751 subjects, 69% females and 81.4% from 
urban areas were assessed (See Table 1). Almost half 
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of participants had family history of diabetes and one 
third had family history of obesity and hypertension. 
Six percent reported have diabetes and around three 
percent had previous cardiovascular disease. Lower 
values of waist circumference, blood pressure, 
Table 1. Demographic and clinics characteristics and cardiometabolic risk factors in the subjects by locality and gender.
Men Women Total
Lara
(Urban)
(n=107)
Páramo 
(Rural) 
(n=51)
Mérida
(Urban) 
(n=71)
Lara
(Urban) 
(n=232)
Páramo 
(Rural) 
(n=89)
Mérida
(Urban) 
(n=201)
Men
(n=229)
Women
(n=522)
Age (years)
45,1
±	1,38
41,1
±	1,38
45,9
±	1,38
46,1	1
±	0,88
40,4	2
±	1,38
46,0	1
±	1,38
44,5
±	1,38
45,1
±	1,38
Body mass index (kg/m2)
28,2a
±	0,53
24,9	b
±	1,38
26,7	a,b
±	1,38
27,2	1
±	0,34
24,9	2
±	1,38
26,7	1
±	1,38
27,0
±	1,38
26,6
±	1,38
Waist Circumference (cm)
99,3*a
±	1,38
91,3	b
±	1,38
92,0	*	b
±	1,38
89,7	1
±	1,38
87,4	2
±	1,38
88,4		2
±	1,38
95,2	*
±	1,38
88,8
±	1,38
Systolic blood pressure 
(mmHg)
124,2*
±	1,38
121,6
±	1,38
122,5
±	1,38
118,6
±	1,38
116,8
±	1,38
118,0
±	1,38
123,1	*
±	1,38
118,0
±	1,38
Diastolic Blood Pressure 
(mmHg)
78,3*
±	1,38
79,6	*
±	1,38
76,1
±	1,38
73,9
±	1,38
75,4
±	1,38
73,4
±	1,38
77,9	*
±	1,38
73,8
±	1,38
Fasting glucose (mg/dl)
95,0	a,b
±	1,38
112,0	*	a
±	1,38
84,6	b
±	1,38
94,9	1
±	1,38
90,3	1,2
±	1,38
82,9	2
±	1,38
96,4	*
±	1,38
90,0
±	1,38
Total cholesterol (mg/dl)
206,6
±	1,38
197.4
±	1.38
195.7
±	1.38
209,4	1
±	1,38
204,0	1,2
±	1,38
192,12
±	1,38
201,6
±	1,38
202,6
±	1,38
HDL cholesterol (mg/dl)
41,1a*
±	1,38
50,3	b
±	1,38
42,4	a
±	1,38
44,1	1
±	1,38
51,4	2
±	1,38
44,5	1
±	1,38
43,6	*
±	1,38
45,5
±	1,38
LDL cholesterol (mg/dl)
127,0
±	1,38
112,5
±	1,38
120,9
±	1,38
134,9	1
±	1,38
123,4	1,2
±	1,38
118,3	2
±	1,38
122,0
±	1,38
127,4
±	1,38
Triglycerides (mg/dl)
225,0*
±	1,38
173,7
±	1,38
157,0
±	1,38
155,2
±	1,38
146,3
±	1,38
149,1
±	1,38
194,9	*
±	1,38
151,5
±	1,38
glucose, and triglycerides; and a higher concentration 
of HDL-c were found in women. Participants living 
in rural areas had lower values of BMI and waist 
circumference, but higher concentrations of glucose 
and HDL-c.
Prevalence of Cardiometabolic Risk 
Factors
Low HDL-c was the most prevalent disorder, 
representing almost two thirds of the participants 
(63.8%), being more common in women than 
men (74.1% vs. 40.4%, respectively; p< 0.05) (See 
table 2). Secondly, abdominal obesity (47.4%) and 
hypertriglyceridemia (45.2%) affected half of the 
sample, this last, was more prevalent in men than 
women (52.8% vs. 41.9%, respectively; p< 0.05) 
(Table 2). 30% of population had hypertension, 
11.8% diabetes, 23.1% obesity, and 20.1% elevated 
LDL-c. When different variables were pooled, 58.5% 
of the subjects have an increased BMI (>25 kg/m2), 
62.3% have raised blood pressure (pre-hypertension 
plus hypertension) and 24.6% presented glucose 
alterations (prediabetes plus diabetes). Metabolic 
syndrome, that compelling three or more alterations, 
was prevalent in 29.9% of the subjects.  
Those subjects from rural area reported 50% less 
prevalence of obesity and low HDL-c than those 
from urban areas (p< 0.05). Only prediabetes was 
higher in the rural sample compared with the Ejido 
Municipality. Lara´s subjects (urban), had the higher 
BMI and a higher prevalence of abdominal obesity, 
atherogenic dyslipidemia, and elevated LDL-c, than 
the other two populations (p < 0.05). 
Values are expressed in mean ± standard error
* Indicate differences between genders from each region and the total by t-test to independent samples.
a,b,c Letters indicate differences between men in the 3 regions by one way ANOVA and Bonferroni test. 
1,2,3 Numbers indicate differences between women in the 3 regions by one way ANOVA and bonferroni test. 
Source: authors.
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Table 2. Prevalence of cardiometabolic risk factors by locality and gender.
Lara 
(Urban n=339)
Páramo 
(Rural n= 140)
Mérida 
(Urban n= 272)
Total
(n= 751)
Obesity (%)
Men
Women
Total
26.4	(18.5-36.0)a
26.8	(21.3-33.1)a
26.7	(22.1-31.8)
11.8	(4.9-24.6)	b
12.4	(6.6	–	21.4)	b
12.1	(7.4	–	19.0)	
21.1(12.7-32.7)	a,b
25.4(19.6-32.1)		a
24.3	(19.4	–	30.0)	
21.5	(16.5-26.5)
23.8	(20.2-27.7)
23.1	(20.2-26.3)
Overweight (%)
Men
Women
Total
45.3	(35.37-55.2)
36.4	(30.2-42.9)	
39.2	(33.9-44.6)
31.4	(19.5	–	46.0)
30.3	(21.8	–	41.1)
30.7	(3.4	–	39.2)
40.8	(29.5	–	53.2)
32.5	(28.9	–	40.6)
34.6	(28.9	–	40.1)
40.8	(34.4-47.5)
33.8	(29.7-38.1)
35.4	(43.8-57.1)
Abdominal obesity (%)
Men
Women
Total
62.3	(52.3-71.3)	*a
49.1	(42.5-55.7)	
53.3	(47.7-58.6)
43.1	(42.3	–	70.8)b
42.7	(46.4	–	67.6)	
42.9	(48.5	–	68.4)	
38.0	(27.0	–	50.4)b
44.3	(37.3	–	51.4)	
42.7	(36.7	–	48.7)	
50.4	(44.8-53.8)
46.2	(41.8-50.6)
47.5	(43.8-51.1)
Pre-diabetes (%)
Men
Women
Total
19.8	(12.9-28.9)	a
14.0	(9.8-19.3)	a
15.8	(12.2-20.3)	
23.5	(13.3	–	37.8)a
15.7	(9.2	–	25.3)	a
18.6	(12.7	–	26.2)		
7.0	(2.3	–	17.8)	b
3.7	(1.5	–	8.2)	b
4.5	(2.3	-8.4)		
17.3(12.6-23.2)a
10.8(8.2-14.0)a,b
12.8	(10.4-15.6)
Diabetes (%)
Men
Women
Total
10.4	(5.5	–	18.2)
11.4	(7.7-16.3)	a,b
11.0	(8.2	–	15.4)	
11.8	(4.9	–	24.6)
6.7	(2.8	–	14.6)a
8.6	(4.7	–	14.8)
15.8	(7.9	–	28.4)
14.6	(9.8	–	21.2)	b
14.9	(10.6	–	20.5)
12.1	(8.2-14.5)
11.6	(8.9-14.9)
11.8	(9.5-14.5)
Pre-hypertension (%)
Men
Women
Total
46.7	(37.1-56.6)	a*
29.3	(23.6-35.7)		
34.8	(29.8-40.1)
25.5(14.8	–	40.0)	b
36.8	(26.9	–	47.9)	
32.6	(25.0	–	41.2)
36.2(25.3	–	48.8)	a,b
26.4	(20.5	–	33.1)
28.9	(23.6	–	34.7)
38.8	(32.5-45.5)a,b
29.4	(25.6-35.6)
32.3	(28.9-35.7)
Hypertension (%)
Men
Women
Total
30.8	(22.5-40.6)
27.2	(21.6-33.4)a,b
28.3	(23.6-33.5)
35.3	(22.8	–	50.0)*
19.5	(12.1	–	27.9)a
25.4	(18.5	–	33.6)
34.8	(24.0	–	47.3)
34.3	(27.9	–	41.4)	b
34.4	(28.8	–	40.5)
33.0	(27.0-39.6)
28.5	(24.8-32.8)
30.0	(26.7-33.4)
Hypercholesterolemia (%)
Men
Women
Total
25.2	(17.6-34.7)	a
24.6	(19.3-30.7)	a
24.8	(20.3-29.8)	
19.6(10.9	–	39.5)a,b
23.6	(15.5	–	34.0)	a
22.1	(15.7	–	30.1)	
8.9	(3.3	–	20.4)	b
12.6	(8.0	–	18.9)	b
11.6	(7.8	–	16.8)
19.6	(14.6-25.7)
20.4	(16.9-24.3)
20.2	(17.3-23.4)
Hypertriglyceridemia (%)
Men
Women
Total
57.0	(47.1-66.4)*
45.3	(38.7-51.9)
49.0	(43.5-54.4)
52.9	(38.6	–	66.8)
40.4	(30.3	–	51.4)
45.0	(36.6	–	53.6)
44.6	(31.6	-58.4)
37.7	(30.3	–	45.8)
39.5	(33.0	–	46.4)
52.8	(45.9-59.6)*c
41.9	(37.4-46.5)
45.2	(41.5-49.0)
Low HDL-c (%)
Men
Women
Total
48.6	(38.9-58.4)*	a
78.0	(72.0-83.0)	a
68.7	(63.5-73.6)	
20.8	(11.0	–	35.4)	*b
55.1(44.2	–	65.5)	b
43.1(34.7	–	51.8)	
41.5	(28.4	–	55.8)	*a
79.2	(71.8	-85.2)	a
69.6	(62.7	–	75.6)	
40.4	(33.7-43.4)*	b
74.1(69.9	-77.9)	b
63.8	(60.1-67.4)
Atherogenic Dyslipidemia 
(%)
Men
Women
Total
32.7	(24.1-42.5)		a
38.8	(32.5-45.4)	a
36.9	(31.7-42.3)	
11.8	(4.9	–	24.6)	b
19.1(11.8	–	29.1)	b
16.4(10.9	–	23.8)	
15.5	(8.6	–	28.5)	b
21.2	(16.5-28.4)	b
20.2	(15.7	–	25.6)	
22.7(17.6-28.8)	b,c
29.0	(25.1-33.1)	a
27.0	(23.9-30.4)	b
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High LDL-c (%)
Men
Women
Total
24.3	(16.7-33.7)	a
26.7	(21.2-32.9)	a
26.0	(21.4-31.0)	
8.3	(2.7	–	20.8)	b
16.9	(10.0-26.6)	a,b
13.9	(8.8	-21.1)	
17.0	(8.5	–	30.3)	a,b
13.8	(8.9	–	20.1)	b
14.6	(10.2	–	20.4)	
18.8	(138-24.9)	b
20.7	(17.2-24.7)
20.1	(17.2-23.4)
Metabolic Syndrome (%)
Men
Women
Total
35.8	(26.9-45.8)		a
34.5	(28.5-41.0)	
34.9	(29.8-40.3)
20.8	(10.9	–	35.4)	b
29.9	(20.8	–	40.8)
26.7	(19.6	–	35.1)
17.0	(8.5	–	30.3)	b
26.1	(19.5	–	34.0)	
23.8	(18.3	–	30.3)
27.5	(21.7-34.2)
30.9	(26.8-35.3)
29.9	(26.5-33.5)
Prevalence is expressed in percentage ± 95% confidence interval.
* Indicate differences between genders from each regions and the total by Chi square.
a,b,c Letters indicate differences between the 3 regions by gender by Chi square.
Source: authors.
Discussion
A high prevalence of cardiometabolic risk factors in 
three populations of Venezuela was found. It was 
characterized for the presence of the metabolic 
syndrome components (low HDL-c, abdominal 
obesity, and hypertryliceridemia) as the most 
frequent alterations. Subjects from urban areas had 
higher BMI and higher frequency of alterations than 
those in the rural area. The prevalence of metabolic 
disorders and hypertension from the rural area was 
reported earlier16,17. 
Worldwide, high blood pressure is estimated to 
cause 7.5 million deaths, about 12.8% of the total of 
all annual deaths by cardiovascular risk18. In Latin 
America, high blood pressure represents the main 
global burden disease19. In fact, hypertension figures 
double for each increase of 20/10 mmHg of blood 
pressure, starting as low as 115/75 mmHg20. In the 
present report, the prevalence of hypertension was 
very high, mainly in the urban area from Mérida 
(34.4%), where ranked as the third highest prevalence 
reported in the country when compared with 
previous reports from the Junquito Municipality21, 
Capital District (43.4%) and Maracaibo city in Zulia 
state (36.9%)22. The prevalence reported in Venezuela 
is similar to the WHO Region of the Americas, with 
35% for both genders18.
The metabolic syndrome represents a cluster 
of abnormalities with great relevance in 
the understanding of physiopathology and 
epidemiologic prevalence of several cardiometabolic 
alterations23. The presence of metabolic syndrome 
as an increasingly entity predicts the risk for 
coronary heart disease, cardiovascular disease, type-
2 diabetes, and overall mortality; compared to its 
individual components24. In this study, the prevalence 
of metabolic syndrome in Lara`s populations was 
very high (34.9%), compared with the CARMELA 
study (25.8%)4 and Zulia state (31.2%)5; however, it`s 
kept below when is compared with the Junquito 
populations (45.4%)21, Catia city, Vargas state (37%)25, 
and Mucuhíes (town), Mérida state (38%)26. The 
prevalence of metabolic syndrome in Mérida city and 
Páramo area (23.8% and 26.7%; respectively) is the 
lowest reported in the country, only above of Sucre 
Municipality, in Miranda state (20%)6. 
The risk of coronary heart disease, stroke and type-
2 diabetes increase steadily with increasing BMI18, 
and the global prevalence of obesity is continually 
growing, increasing from 3.2% in 1975 to 10.8% in 
2014 in men, and from 6.4% to 14.9% in women27. The 
prevalence of obesity found in the rural sample of 
this study is the lowest reported in Venezuela (12.1%), 
being the half of the observed in the urban areas 
(24.3% and 26.7%, Merida - Lara, respectively), and one 
third of the observed in Catia (35%)25, and Valencia 
city, Carabobo state (39%)28. This low prevalence 
of obesity in the rural area could be explained by 
agrarian life style, but more studies in other rural 
areas of the country are necessary.
The global age-standardized diabetes prevalence 
increased from 4.3% in 1980 to 9.0% in 2014 in men, 
and from 5.0% to 7.9% in women, representing 
more than 422 millions of subjects with diabetes 
around the world29. Most people with diabetes live 
in low- and middle-income countries and these will 
experience the greatest increase in cases of diabetes 
over the next 22 years30. The prevalence of diabetes 
reported in the urban areas of the present study is 
the highest reported in Venezuela (14.9%, and 11.0%, 
in Merida City and Lara, respectively), doubling the 
observed in Barquisimeto in the CARMELA study 
(6%)31, the Zulia state (7.8% and 7.4% to men and 
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women, respectively)5 and the weighed prevalence 
of all the previous studies in Venezuela (7.7%)32.
Raised total cholesterol is a major cause of disease 
burden, in both the developed and developing 
world, as a risk factor for ischemic heart disease 
and stroke18. The prevalence of hypercolesterolemia 
observed in our report in Lara populations (24.8%) 
quintupled the observed in the same population 
in the CARMELA study (5.7%),4 but, is significant 
lower when it’s compared with Valencia city, (59%)28 
and Zulia state (39.3%)33.  In 2008, the worldwide 
prevalence of raised total cholesterol among adults 
was 39% (37% for males and 40% for females)18, figure 
that duplicate the prevalence reported in this study 
(20.2%). Low HDL-c is highly prevalent in Venezuela. 
In the urban populations evaluated, the prevalence 
of low HDL-c was 68.7% in Lara and 69.6% in Mérida 
city, which correspond with the reported in Zulia 
state (65.3%)5, but is lower than the one reported in 
the Junquito, Capital District  (81.1%)21, and Valencia 
city (90%)28. The lowest prevalence of low HDL-c 
reported in Venezuela is in Sucre Municipality, 
Miranda state (42.9%) and in the Paramo area, 
Mérida state (43.1%). High prevalence of low HDL-c 
levels has been reported in Mexico (64.7%)34 and in 
other Latin populations35-37. It is pending to elucidate 
the mechanisms (exercise, diet, genetics) involved in 
these inter-ethnic and inter-regional differences.
Some limitations can be observed in the present 
study. The sample did not represent the entire 
population of the country, only two of the eight 
regions of Venezuela were included. Additionally, in 
the VEMSOLS, eating pattern and physical activity was 
not investigated. However, despite these limitations, 
this study is the first report of cardiometabolic risk 
factors in more than one region of Venezuela. 
Conclusion 
This is the first report of the evaluation under 
the same methodology of the prevalence of 
cardiometabolic risk factors in three populations 
from Venezuela that included a rural area. In general, 
the prevalence of these cardiometabolic alterations 
was high in these populations. In the rural area, 
people was leaner and presented the highest levels 
of HDL-c, however, the figures reported are similar 
to those obtained in other regions of the country. 
This elevated prevalence of cardiometabolic 
risk factors will carry on an increased number of 
preventable cardiovascular events imposing a big 
load on the Venezuelan public health services. 
Major interventions, including clinical physicians and 
policymakers, are required to improve population 
health. In 2017 was completed the Venezuelan 
Study of Cardio-Metabolic Health (EVESCAM, for 
its acronym in Spanish) which evaluated the entire 
country and will allow us compare will other regions 
not previously evaluated.    
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